NewAmsterdam Pharma Q3 net loss widens to $72M; EMA accepts MAAs for obicetrapib

NewAmsterdam Pharma Co N.V.

2025-Q3 EPS reported -$1.09 revenue$22,471,000

Cash, equivalents and securities $756M as of Sep 30, 2025, down from $834.2M at Dec 31, 2024.
Net loss $72.0M in Q3 2025 vs $16.6M loss in Q3 2024; revenue fell to $0.3M from $29.1M.
European Medicines Agency accepted MAAs for obicetrapib monotherapy and FDC with ezetimibe.
R&D expenses $31.0M (down 13% YoY); SG&A $24.5M (up 33% YoY), driven by personnel and share-based compensation.
Ongoing Phase 3 trials: PREVAIL CVOT (>9,500 enrolled), REMBRANDT plaque imaging, and RUBENS (diabetes) expected Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.